1-3 of 3
Anja Seckinger
Close
Sort by
Journal Articles

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

Clinical Trials & Observations
Jacob Stroh, Anja Seckinger, Michael Heider, Martina Rudelius, Ruth Eichner, Markus Schick, Jolanta Slawska, Martina Emde-Rajaratnam, Hans Salwender, Uta Bertsch, Hartmut Goldschmidt, Katja Weisel, Christof Scheid, Ulrich Keller, Dirk Hose, Florian Bassermann
Journal: Blood Advances
Blood Adv (2022) 6 (2): 515–520.
https://doi.org/10.1182/bloodadvances.2021005532
Published: 2022
Includes: Supplemental data
Journal Articles

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, Martin Granzow, Korbinian Hoffmann, Alwin Krämer, Marc-Steffen Raab, Jens Hillengass, Anja Seckinger, Christoph Kimmich, Tobias Dittrich, Carsten Müller-Tidow, Dirk Hose, Hartmut Goldschmidt, Ute Hegenbart, Anna Jauch, Stefan O. Schönland
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2607–2618.
https://doi.org/10.1182/bloodadvances.2018023200
Published: 2018
Includes: Supplemental data
Journal Articles

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Clinical Trials & Observations
Maximilian Merz, Anna Jauch, Thomas Hielscher, Tilmann Bochtler, Stefan Olaf Schönland, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc Steffen Raab, Jens Hillengass, Hans Salwender, Igor Wolfgang Blau, Hans-Walter Lindemann, Ingo G. H. Schmidt-Wolf, Christof Scheid, Mathias Haenel, Katja C. Weisel, Hartmut Goldschmidt
Journal: Blood Advances
Blood Adv (2017) 2 (1): 1–9.
https://doi.org/10.1182/bloodadvances.2017013334
Published: 2017
Includes: Supplemental data